Stratagene Announces Third Quarter 2006 Earnings Release Date and Conference Call

  
    
  
  
    
      Stratagene Corporation (NASDAQ:STGN), today announced that it will 
      release third quarter financial results on Monday, November 13, 
      2006 after the market close. The Company will also host a 
      conference call and webcast on Monday, November 13, 2006 at 
      1:30 p.m. Pacific Time to discuss the Company’s 
      third quarter results, outlook for the remainder of 2006, and current 
      corporate developments. The dial-in number for the conference call is 
      800-218-8862 for domestic participants and 303-262-2142 for 
      international participants.
    
    
      A taped replay of the conference call will also be available beginning 
      approximately one hour after the call’s 
      conclusion and will remain available for 7 days. It can be accessed by 
      dialing 800-405-2236 for domestic callers and 303-590-3000 for 
      international callers, using the passcode 11074147#. To access the live 
      webcast of the call, go to Stratagene’s 
      website at www.stratagene.com 
      and click on the Investors icon. An archived webcast will also be 
      available at www.stratagene.com.
    
    
      About Stratagene Corporation
    
    
      Stratagene is a developer, manufacturer and marketer of specialized life 
      science research and diagnostic products. The Company's life science 
      research unit supports advances in science by inventing, manufacturing 
      and distributing products that simplify, accelerate and improve 
      research. These products are used throughout the academic, industrial 
      and government research sectors in fields spanning molecular biology, 
      genomics, proteomics, drug discovery and toxicology. The Company's 
      diagnostic unit develops and manufactures products for urinalysis as 
      well as high quality automated instrument and reagent systems that use 
      blood samples to test for more than 1,000 different allergies and 
      autoimmune disorders. In addition, by combining its expertise in 
      diagnostics and molecular biology, as well as its experience with FDA 
      regulatory procedures, the Company is pursuing opportunities to expand 
      its product portfolio to include molecular diagnostic kits and 
      instrumentation. More information is available at www.stratagene.com.
    
  
Stratagene Corporation (NASDAQ:STGN), today announced that it will
release third quarter financial results on Monday, November 13, 2006
after the market close. The Company will also host a conference call
and webcast on Monday, November 13, 2006 at 1:30 p.m. Pacific Time to
discuss the Company's third quarter results, outlook for the remainder
of 2006, and current corporate developments. The dial-in number for
the conference call is 800-218-8862 for domestic participants and
303-262-2142 for international participants.

   A taped replay of the conference call will also be available
beginning approximately one hour after the call's conclusion and will
remain available for 7 days. It can be accessed by dialing
800-405-2236 for domestic callers and 303-590-3000 for international
callers, using the passcode 11074147#. To access the live webcast of
the call, go to Stratagene's website at www.stratagene.com and click
on the Investors icon. An archived webcast will also be available at
www.stratagene.com.

   About Stratagene Corporation

   Stratagene is a developer, manufacturer and marketer of
specialized life science research and diagnostic products. The
Company's life science research unit supports advances in science by
inventing, manufacturing and distributing products that simplify,
accelerate and improve research. These products are used throughout
the academic, industrial and government research sectors in fields
spanning molecular biology, genomics, proteomics, drug discovery and
toxicology. The Company's diagnostic unit develops and manufactures
products for urinalysis as well as high quality automated instrument
and reagent systems that use blood samples to test for more than 1,000
different allergies and autoimmune disorders. In addition, by
combining its expertise in diagnostics and molecular biology, as well
as its experience with FDA regulatory procedures, the Company is
pursuing opportunities to expand its product portfolio to include
molecular diagnostic kits and instrumentation. More information is
available at www.stratagene.com.